Nintedanib plus chemotherapy for non-small cell lung cancer with IPF: a randomized phase 3 trial.
Eur Respir J. 2022 Mar 31:2200380. doi: 10.1183/13993003.00380-2022. Online ahead of print.
Eur Respir J. 2022.
PMID: 35361630